Physicochemical properties of JS@GO nanofluid and its potential in enhanced oil recovery

Employing nanofluid flooding as an advanced enhanced oil recovery (EOR) technique has emerged as a groundbreaking approach for the extraction of residual hydrocarbons from increasingly depleted reservoirs. The innovative utilization of nanocomposites, specifically Janus SiO2 (JS) particles amalgamated with graphene oxide (GO), constitutes the focus of this research. We elucidate how this novel JS@GO nanocomposite enhances oil displacement through its exemplary interfacial activity, substantiated by various empirical evaluations such as contact angle and interfacial tension tests. Moreover, core flooding experiments corroborate the nanocomposite’s superior efficiency in augmenting oil recovery vis-a-vis traditional methodologies, which was due to the improvement of both emulsifying ability and amphiphilicity. The results of this research underscore the considerable promise the JS@GO nanofluid holds for future EOR applications, providing a compelling alternative for revitalizing oil production from heretofore unyielding reservoirs. Nanofluid flooding is recognized as an innovative EOR technique for residual oil. A novel JS@GO nanocomposite was successfully synthesized for EOR application. Interfacial activity of JS@GO was assessed using contact angle and IFT tests. Core flooding experiments underscore JS@GO nanofluid’s superior oil recovery capability. </p

Association between postoperative ibuprofen exposure and acute kidney injury after pediatric cardiac surgery

Acute kidney injury (AKI) is a common complication after pediatric cardiac surgery and is associated with worse outcomes. Ibuprofen is widely used in the perioperative period and can affect kidney function in children. However, the association between ibuprofen exposure and AKI after pediatric cardiac surgery has not been determined yet. In this retrospective cohort study, children undergoing cardiac surgery with cardiopulmonary bypass were studied. Exposure was defined as given ibuprofen in the first 7 days after surgery. Postoperative AKI was diagnosed using the KDIGO criteria. A multivariable Cox regression model was used to assess the association between ibuprofen exposure and postoperative AKI by taking ibuprofen as a time-varying covariate. Among 1,112 included children, 198 of them (17.8%) experienced AKI. In total, 396 children (35.6%) were exposed to ibuprofen. AKI occurred less frequently among children who were administered ibuprofen than among those who were not (46 of 396 [11.6%] vs. 152 of 716 [21.2%], p p = 0.932). This insignificant association was consistent across the sensitivity and subgroup analyses. Postoperative ibuprofen exposure in pediatric patients undergoing cardiac surgery was not associated with an increased risk of AKI.</p

The methods about measurements of radiographic parameters.

<p>The range of motion (ROM) at the adjacent levels by disc space angle in the Discover group (a). The overall alignment of C2-C7 (α,OSA) and functional spinal unit (β,FSU) angle in the Discover group (b). The range of motion (ROM) at the adjacent levels by disc space angle in the Zero-P group (c). The overall alignment of C2-C7 (α,OSA) and functional spinal unit (β,FSU) angle in the Zero-P group (d).</p

Comparison of radiographic outcomes between the 2 groups.

<p>Comparison of radiographic outcomes between the 2 groups.</p

The representive case who suffered migration of Discover prothesis postoperatively.

<p>Postoperative 2-day (a), and final follow-up (b) lateral radiographs showing anterior migration of the superior endplate of Discover prosthesis (White arrows).</p

The representive case who suffered prosthesis subsidence and adjacent disc degeneration postoperatively.

<p>Postoperative 2-day (a), and final follow-up (b) lateral radiographs showing the superior endplate of Discover prosthesis subsiding into the cephalad vertebra and new anterior osteophyte formation in the patient after cervical disc arthroplasty with Discover prothesis. The white arrows indicate the subsidence of the prosthesis. The black arrows indicate the new anterior osteophyte formation.</p

Purification and identification of rColH (E451D).

(A) The process flow chart of purification with five chromatography steps. (B) SDS-PAGE of rColH(E451D) protein after five purification steps. (C) SEC and CE-SDS results of rColH(E451D) protein. (D) Q-TOF-MS of rColH(E451D) protein from three continuous batches. The theoretical molecular weight of rColH(E451D) is 112,009 Da.</p

Histopathology evaluation results by H&E and masson staining.

(A) H&E staining of adipose tissues from the placebo and 0.075/0.15/0.30 mg/injection areas. Scale bar = 0.5 mm. (B) Masson staining of adipose tissues from the placebo and 0.075/0.15/0.30 mg/injection areas. Scale bar = 0.5 mm. (C) The scores of histological parameters (fibrosis, cholesterol cleft, inflammation and necrosis). Data are presented as the mean ± SD, n = 12 (4 sections/area/minipig, 3 minipigs).</p

The adipolysis study <i>in vitro</i> and <i>in vivo</i>.

(A) The efficacy of rColH(FM) on isolated adipose tissues from ob/ob mice was tested in vitro. (B) rColH(E451D) could obviously cause the adipolysis of adipose tissues from a minipig in vitro at 37°C in 5 h. Lipolysis was observed at injection sites after the oily liquid was removed manually (see red arrows). (C) Pharmacodynamics study schematic showing the subcutaneous injection of rColH(E451D) into the back adipose tissues of minipigs. (D) The thickness of adipose tissues was measured weekly by ultrasonography, and the results of areas C & D are shown. (E) Statistical analysis of the ultrasound results for all groups are listed. Data are presented as the mean ± SD, n = 3.</p

The representive case who suffered heterotopic ossification of Discover prosthesis postoperatively.

<p>Dynamic flexion-extension lateral radiographs at the final follow-up showing heterotopic ossification (Grade III) at the index level with significant restriction in the range of motion of Discover prothesis.</p